• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Med Microbiol Immunol . Ten rapid antigen tests for SARS-CoV-2 widely differ in their ability to detect Omicron-BA.4 and -BA.5

tetano

Editor, Senior Moderator
Med Microbiol Immunol


. 2023 Aug 10.
doi: 10.1007/s00430-023-00775-8. Online ahead of print. Ten rapid antigen tests for SARS-CoV-2 widely differ in their ability to detect Omicron-BA.4 and -BA.5

Franziska Krenn[SUP] 1 [/SUP], Christopher Dächert[SUP] 1 2 [/SUP], Irina Badell[SUP] 1 [/SUP], Gaia Lupoli[SUP] 1 [/SUP], Gamze Naz Öztan[SUP] 1 [/SUP], Tianle Feng[SUP] 1 [/SUP], Nikolas Schneider[SUP] 1 [/SUP], Melanie Huber[SUP] 1 [/SUP], Hanna Both[SUP] 1 [/SUP], Patricia M Späth[SUP] 1 [/SUP], Maximilian Muenchhoff[SUP] 1 2 3 [/SUP], Alexander Graf[SUP] 4 [/SUP], Stefan Krebs[SUP] 4 [/SUP], Helmut Blum[SUP] 4 [/SUP], Jürgen Durner[SUP] 5 [/SUP], Ludwig Czibere[SUP] 5 [/SUP], Lars Kaderali[SUP] 6 [/SUP], Oliver T Keppler[SUP] 7 8 9 [/SUP], Hanna-Mari Baldauf[SUP] 10 [/SUP], Andreas Osterman[SUP] 11 [/SUP]



Affiliations
Abstract

Since late 2021, the variant landscape of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been dominated by the variant of concern (VoC) Omicron and its sublineages. We and others have shown that the detection of Omicron-BA.1 and -BA.2-positive respiratory specimens by rapid antigen tests (RATs) is impaired compared to Delta VoC-containing samples. Here, in a single-center retrospective laboratory study, we evaluated the performance of ten most commonly used RATs for the detection of Omicron-BA.4 and -BA.5 infections. We used 171 respiratory swab specimens from SARS-CoV-2 RNA-positive patients, of which 71 were classified as BA.4 and 100 as BA.5. All swabs were collected between July and September 2022. 50 SARS-CoV-2 PCR-negative samples from healthy individuals, collected in October 2022, showed high specificity in 9 out of 10 RATs. When assessing analytical sensitivity using clinical specimens, the 50% limit of detection (LoD50) ranged from 7.6 × 10[SUP]4[/SUP] to 3.3 × 10[SUP]6[/SUP] RNA copies subjected to the RATs for BA.4 compared to 6.8 × 10[SUP]4[/SUP] to 3.0 × 10[SUP]6[/SUP] for BA.5. Overall, intra-assay differences for the detection of these two Omicron subvariants were not significant for both respiratory swabs and tissue culture-expanded virus isolates. In contrast, marked heterogeneity was observed among the ten RATs: to be positive in these point-of-care tests, up to 443-fold (BA.4) and up to 56-fold (BA.5) higher viral loads were required for the worst performing RAT compared to the best performing RAT. True-positive rates for Omicron-BA.4- or -BA.5-containing specimens in the highest viral load category (C[SUB]t[/SUB] values < 25) ranged from 94.3 to 34.3%, dropping to 25.6 to 0% for samples with intermediate C[SUB]t[/SUB] values (25-30). We conclude that the high heterogeneity in the performance of commonly used RATs remains a challenge for the general public to obtain reliable results in the evolving Omicron subvariant-driven pandemic.

Keywords: Diagnostic test; Lateral flow; Nucleocapsid protein; Omicron; SARS-CoV-2 rapid antigen test; Sensitivity; Specificity; VoC.

 
Back
Top Bottom